Drug reference
tesamorelin
Growth hormone-releasing hormone analogue · Treatment of HIV-associated lipodystrophy
Growth hormone-releasing hormone analogueTreatment of HIV-associated lipodystrophy
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Tesamorelin is a synthetic N-terminally modified form of human GHRH that is resistant to degradation by dipeptidyl peptidase 4. Although it increases GH and IGF-1 levels, its clinical effects are primarily to reduce visceral fat accumulation, with minimal effects on insulin resistance.
Indications
HIV-associated lipodystrophy
Pharmacokinetics
Duration
prolonged duration of action
Drug interactions
12 additional unreviewed or low-confidence interactions hidden because their provenance or source detail is insufficient.
Related guidelines
Ask House about tesamorelin
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: Goodman & Gilman 14e·Updated: 2026-05-10